All In Biotech

Drug Trial Radar · NCT03718806

Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin

A Phase 1, Open-Label, Study to Investigate Pharmacokinetics, Effect of Food and Safety of a New Immediate-Release Formulation of Zoliflodacin in Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Dec 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Oct 3, 2018

Primary completion

Nov 12, 2018

Study completion Nov 12, 2018

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Quotient Sciences
First posted
Oct 24, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I, parallel, open-label, randomized, cross-over, single-center study with zoliflodacin administered as granules for oral suspension with or without food. It is planned to enroll 2 cohorts (Cohorts 1 and 2) of 24 subjects each (48 subjects in total), with the target of achieving data in 20 evaluable subjects per cohort. Single doses of zoliflodacin will be assessed within each cohort in a two period cross-over design. Each subject will receive one of the following regimens per period, depending on cohort, in a sequence according to the randomization schedule (per cohort, subjects will be randomized immediately before dosing in Period 1), separated by a minimum 4 day washout between each period. The actual length of washout period may change pending emerging PK data. Cohort 1: * Regimen A: 3 g zoliflodacin oral suspension; oral administration after an overnight fast * Regimen B: 3 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast Cohort 2 * Regimen C: 4 g zoliflodacin oral suspension; oral administration after an overnight fast * Regimen D: 4 g zoliflodacin oral suspension; oral administration with a standardized high calorie, high-fat breakfast

Conditions

  • Gonorrhea

Interventions

  • ZoliflodacinDrug

    oral suspension; oral administration

  • high calorie, high fat breakfastOther

    fasted/fed conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. PK parameter of zoliflodacin : CmaxTime frame: Day 3
  2. PK parameter of zoliflodacin : TmaxTime frame: Day 3
  3. PK parameter of zoliflodacin : AUCTime frame: Day 3
  4. PK parameter of zoliflodacin : T1/2Time frame: Day 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.